 |
|
|
| |
MATERNAL DOLUTEGRAVIR (DTG) USE, AND PREGNANCY
AND BIRTH OUTCOMES: THE ANTIRETROVIRAL PREGNANCY REGISTRY (APR)
|
| |
| |
IDWeek 2021 Sept 29-Oct 3
Vani Vannappagari,1,2 Jessica D. Albano,3 Leigh Ragone,1 Taylor Cook,3 Angela E. Scheuerle,4 William R. Short,5 Claire Thorne,6 Karen Beckerman,7 Nahida Chakhtoura,8 Lynne Mofenson9
1ViiV Healthcare, Research Triangle Park, NC, USA; 2Gillings School of Global Public Health, University of North Carolina-Chapel Hill, Chapel Hill, NC, USA; 3Syneos Health, Wilmington, NC, USA; 4University of Texas Southwestern Medical Center, Dallas, TX, USA; 5The Perelman School of Medicine, University of Pennsylvania, Philadelphia PA, USA; 6University College London Great Ormond Street Institute of Child Health, London, UK; 7Carl Icahn School of Medicine at Mt Sinai, BronxCare Health System, Bronx, NY, USA;
8Eunice Kennedy Shriver NICHD, National Institutes of Health, Bethesda MD, USA; 9Elizabeth Glaser Pediatric AIDS Foundation, Washington, DC, USA
|
| |
|
|
|
|
|
